PerkinElmer
check quantity

IVISense Vascular NP 680 Fluorescent Nanoparticles (AngioSPARK)

IVISense Vascular NP (AngioSPARK®) is a fluorescent nanoparticle probe with a long pharmacokinetic profile for imaging vascularity, vascular leak, blood-brain-barrier compromise, and vascular cell fluid-phase pinocytosis.

PerkinElmer's IVISense Vascular NP fluorescent nanoparticle probes are available in 680 and 750 nm wavelengths ideal for multiplexing with other probes.

For research use only. Not for use in diagnostic procedures.

Part Number
SKU Display Name
List Price
Your Price
Quantity
NEV10149
IVISense Vascular NP 680 Fluorescent Nanoparticles (AngioSPARK)
890.00 USD
 
more
NEV10150
IVISense Vascular NP 750 Fluorescent Nanoparticles (AngioSPARK)
890.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

IVISense Vascular NP 680 is a highly fluorescent near-infrared nanoparticle probe specifically designed for in vivo imaging. IVISense Vascular NP 680 contains an iron oxide core that is coated to specifically produce a functionalized biocompatible probe comprised of a pegylated fluorescent nanoparticle that remains localized in the vasculature for extended periods of time and enables imaging of blood vessels, angiogenesis, blood-brain-barrier compromise, and vascular cell fluid-phase pinocytotic function. IVISense Vascular NP 680 fluorescent nanoparticle probe can also be used at later time points (>12 hours) to image vascular leak in tissue site of inflammation and cancer. IVISense Vascular NP 680 can be imaged within the interstitium for up to 24 hours post tail vein injection.

Benefits of IVISense Vascular NP fluorescent nanoparticles

  • Highly fluorescent near infrared nanoparticles specifically designed for in vivo vascular imaging.
    • Contain an iron oxide core that is coated to specifically produce a functionalized biocompatible product.
    • Pegylation facilitates extended blood half-life to enable imaging of blood vessels and angiogenesis.
  • Imaging of vascularity, perfusion, and vascular permeability. Long pharmacokinetic profile.
  • Long-term tissue accumulation in chronic inflammation and cancer/angiogenesis studies.
  • Vascularity in cancer and inflammation by noninvasive and intravital microscopy.
  • Assessment of CNS blood-brain-barrier compromise.
  • in vivo assessment of vascular fluid-phase pinocytosis in atherosclerosis
  • Can also be used at later time points (>12 hours) to image vascular leak in tissue site of inflammation and cancer.
  • Can be imaged within the interstitium for up to 24 hours post tail vein injection.

Specifications

Fluorescent Agent Type Vascular
Optical Imaging Classification Fluorescence Imaging
Product Brand Name IVISense
Quantity in a Package Amount 1.0 Units
Shipping Condition Ambient
Therapeutic Area Vascular disease, Angiogenesis, Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer
Unit Size 1 Vial (5 doses)
Wave Length 680 nm
Resources, Events & More
  • All

Application Note

Vascular Imaging Probes For Oncology and Inflammation Using the IVIS Spectrum

Optical-based in vivo imaging of vascular changes and vascular leak is an emerging modality for studying altered physiology in a variety of different cancers and inflammatory states. A number of fluorescent imaging probes that circulate with the blood, but have no target selectivity, have been used to detect tumor leakiness as an indication of abnormal tumor vasculature. Inflammation is also characterized by distinct vascular changes, including vasodilation and increased vascular permeability, which are induced by the actions of various inflammatory mediators. This process is essential for facilitating access for appropriate cells, cytokines, and other factors to tissue sites in need of healing or protection from infection. This application note investigates the use of three fluorescent imaging probes, to detect and monitor vascular leak and inflammation in preclinical mouse breast cancer models.

PDF 4 MB

Ebook

In Vivo Imaging Solutions eBook

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.

PDF 4 MB

Flyer

Best Practices for Designing An Effective In Vivo Fluorescence Imaging Study

Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.

Learn about several important best practices, from proper probe selection to study design to imaging technique tips and tricks needed to generate meaningful biological information from your in vivo fluorescence imaging studies.

PDF 507 KB

Technical Note

AngioSPARK® 680 NanoSPARK™ (Data Sheet)

NanoSPARKS™ are a new family of highly fluorescent near infrared nanoparticles specifically designed for in vivo imaging. NanoSPARKS contain an iron oxide core that is coated to specifically produce a functionalized biocompatible product. AngioSPARK® 680 comprises pegylated fluorescent nanoparticles that remain localized in the vasculature for extended periods of time and enable imaging of blood vessels and angiogenesis.

PDF 53 KB

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 547 KB